A clinical overview of infection in patients receiving elranatamab (ELRA) in combination with daratumumab (DARA) and lenalidomide (R) for newly diagnosed multiple myeloma in the MagnetisMM-6 trial


Por: Byun, JM, Pour, L, Minarik, J, Prince, HM, Askari, E, Yeh, SP, Oriol, A, Ito, S, White, D, Shaikh, E, Green, NN, Leip, E, Viqueira, A and Quach, H

Publicada: 1 dic 2025 Ahead of Print: 1 dic 2025
Resumen:


Filiaciones:
Byun, JM:
 Seoul Natl Univ, Coll Med, Seoul Natl Univ Hosp, Dept Internal Med, Seoul, South Korea

Pour, L:
 Univ Hosp Brno, Dept Internal Med Hematol & Oncol, Brno, Czech Republic

Minarik, J:
 Univ Hosp Olomouc, Dept Hemato Oncol, Olomouc, Czech Republic

Prince, HM:
 Epworth Healthcare, Melbourne, Vic, Australia

 Univ Melbourne, Melbourne, Australia

Askari, E:
 Hosp Univ Fundacibn Jimenez Diaz, Dept Hematol, Madrid, Spain

Yeh, SP:
 China Med Univ Hosp, Hematol Dept, Taichung, Taiwan

:
 Hosp Germans Trias i Pujol, Inst Catala Oncol, Barcelona, Spain

 Hosp Germans Trias i Pujol, Inst Josep Carreras, Barcelona, Spain

Ito, S:
 Yamagata Univ Grad Sch Med, Dept Internal Med 3, Div Hematol & Cell Therapy, Yamagata, Japan

White, D:
 Dalhousie Univ, Div Hematol, Halifax, NS, Canada

 Queen Elizabeth 2 Hlth Sci Ctr, Halifax, NS, Canada

Shaikh, E:
 Pfizer Inc, Bothell, WA USA

Green, NN:
 Pfizer Inc, Cambridge, MA USA

Leip, E:
 Pfizer Inc, Cambridge, MA USA

Viqueira, A:
 Pfizer SLU, Madrid, Spain

Quach, H:
 Univ Melbourne, St Vincents Hosp Melbourne, Melbourne, Australia
ISSN: 00064971





Blood
Editorial
American Society of Hematology, 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA, Estados Unidos America
Tipo de documento: Meeting Abstract
Volumen: 146 Número:
Páginas: 2253-2254
WOS Id: 001660396400003
imagen Bronze

MÉTRICAS